With a strong global profile and powerful experience of building up and turning around life science startups, Ann will begin her role as new CEO for Ziccum on May 9. Ann combines long-running experience in designing and implementing new business models with a passion for creating new partnerships and achieving steep, sustainable growth.

Most recently Ann Gidner was CEO for SelectImmune Pharma AB (publ). She has served in CEO positions for AcuCort AB (publ) and Monocl AB and is currently a Director of the board at IcoNovo AB (publ). Ann has also held senior management roles in Life Science corporations across Europe, and in the US. In a 4-yr role as Director of Business Development for drug delivery technology company Albumedix A/S (formerly Novozymes Biopharma), she successfully established a pipeline and network of new partnerships and projects from the company’s headquarters in Copenhagen.

Ann has an MBA from Lund University and a MSc in Bioprocessing Engineering from Lund University and the elite ENSIGC (Ecole Nationale Supérieure d'Ingénieurs de Génie Chimique in Toulouse, France). She is a multilinguistic who is fluent in three languages.

Ziccum AB CEO Fredrik Sjövall: “We could not be happier in welcoming Ann to Ziccum. Her keen mind and outstanding leadership record speaks for itself. Her strategic insights and business development acumen will profoundly help us power new partnerships, patents and product development. The company is changing and moving forward – Ann will be pivotal to that. It will be truly exciting to have her onboard.”

Ann Gidner: “Ziccum AB offers a unique technology to serve the world far better with vaccinations, overcoming a number of financial and practical hurdles. Of course the Covid pandemic has emphazised how valuable this is to mankind. I am grateful and excited to contribute to this, joining a high caliber team to create the necessary outreach, both for company success and for global health.”